Threshold Pharmaceuticals, Inc., based in South San Francisco,
California, is a research-driven biotechnology company dedicated to the discovery and development of tumor targeted therapies to improve the lives of patients with cancer.
- September 2, 2014
- Threshold Pharmaceuticals Announces Presentation and Webcast at the Rodman & Renshaw 16th Annual Global Investment Conference
- August 1, 2014
- Threshold Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
- July 9, 2014
- Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma